Q2 FY2027 · ended Sep 26, 2026 · Revenue $357.76M, +9.3% YoY · Filed Nov 5, 2026
Haemonetics Corporation (HAE) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In Q2 of fiscal 2027, the quarter ended Sep 26, 2026, it reported revenue of $357.8 million and net income of $46.3 million. Free cash flow was $113.3 million. As of Sep 26, 2026 it held $260.7 million in cash and investments and $1.1 billion in total debt.
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- HAE (NYSE)
- Fiscal year ends
- April 3
- Incorporated in
- MA
- Headquarters
- Boston, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 313143
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2027 Sep 26, 2026 |
Q1 FY2027 Jun 27, 2026 |
Q4 FY2026 Mar 28, 2026 |
Q3 FY2026 Dec 27, 2025 |
Q2 FY2026 Sep 27, 2025 |
|---|---|---|---|---|---|
| Revenue | $357.8M | $339.4M | $346.4M | $339.0M | $327.3M |
| Operating income | $75.1M | $57.5M | -$23.0M | $67.4M | $58.5M |
| Net income | $46.3M | $33.0M | -$20.1M | $44.7M | $38.7M |
| Diluted EPS | $1.00 | $0.72 | -$0.43 | $0.95 | $0.81 |
| Operating cash flow | $128.1M | $52.3M | $70.9M | $93.6M | $111.3M |
| Free cash flow | $113.3M | $44.4M | $53.3M | $87.2M | $106.3M |
| Total assets | $2.4B | $2.4B | $2.4B | $2.5B | $2.4B |
| Stockholders' equity | $898.5M | $837.1M | $796.3M | $911.5M | $849.2M |
| Cash and investments | $260.7M | $223.4M | $245.4M | $363.4M | $296.4M |
| Total debt | $1.1B | $1.2B | $1.3B | $1.2B | $1.2B |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 26, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 5, 2026 | Nov 5, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 8, 2026 | Oct 8, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Aug 18, 2026 | Aug 18, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 27, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
All 1002 Haemonetics Corporation SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.